Sugi Predict

Sugi Predict / Compounds / SCHEMBL3695378

SCHEMBL3695378

SCHEMBL3695378

CCOC(=O)C(=CN(C)C)C(=O)c1cc(F)c(F)c(F)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ NPSR1 Q6W5P4 4/20 0.40
▸ MAPT P10636 3/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ CYP11B1 P15538 3/20 0.36
▸ CYP11B2 P19099 3/20 0.36
▸ GLO1 Q04760 1/20 0.35
▸ S1PR4 O95977 1/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ USP2 O75604 1/20 0.34
▸ IDE P14735 1/20 0.34
▸ TNNI3 P19429 1/20 0.34
▸ TNNT2 P45379 1/20 0.34
▸ TNNC1 P63316 1/20 0.34
▸ HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30843044 1.00 MEN1 (0.40) MEN1KMT2ANPSR1MAPTCYP2C9
SCHEMBL4567521 1.00 MEN1 (0.40) MEN1KMT2ANPSR1MAPTCYP2C9
SCHEMBL9561731 1.00 MEN1 (0.40) MEN1KMT2ANPSR1MAPTCYP2C9
SCHEMBL7519192 0.91 MEN1 (0.40) MEN1KMT2ANPSR1MAPTCYP2C9
SCHEMBL7519196 0.91 MEN1 (0.40) MEN1KMT2ANPSR1MAPTCYP2C9
SCHEMBL9212344 0.88 CYP2C9 (0.40) MEN1KMT2ANPSR1MAPTCYP2C9
SCHEMBL9562415 0.88 CYP2C9 (0.40) MEN1KMT2ANPSR1MAPTCYP2C9
SCHEMBL9562231 0.88 KMT2A (0.40) MEN1KMT2ANPSR1MAPTCYP2C9
SCHEMBL9213709 0.88 KMT2A (0.40) MEN1KMT2ANPSR1MAPTCYP2C9
SCHEMBL4887115 0.88 CES2 (0.49) MEN1KMT2ANPSR1MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115703757-B Synthesis method of melaxacin 浙江中欣氟材股份有限公司 2024-04-09 — — CN claimed
CN-115703757-A Synthesis method of melafloxacin 浙江中欣氟材股份有限公司 2023-02-17 — — CN claimed
CN-105968025-B The preparation method of 3- (methylbenzylamide) -2- (2,3,4,5- tetrafluoros benzoyl) ethyl acrylate 河北科技大学 2018-04-27 — — CN disclosed
US-20120122804-A1 SUBSTITUTED QUINOBENZOXAZINE ANALOGS CYLENE PHARMACEUTICALS, INC. (US) 2012-05-17 — — US disclosed
US-20120122804-A1 SUBSTITUTED QUINOBENZOXAZINE ANALOGS CYLENE PHARMACEUTICALS, INC. (US) 2012-05-17 — — US disclosed
US-20110065687-A1 HYDRAZIDE COMPOUNDS AND USES THEREOF SENHWA BIOSCIENCES, INC. (TW) 2011-03-17 — — US disclosed
US-20110065687-A1 HYDRAZIDE COMPOUNDS AND USES THEREOF SENHWA BIOSCIENCES, INC. (TW) 2011-03-17 — — US disclosed
US-7612063-B2 Substituted quinobenzoxazine analogs CYLENE PHARMACEUTICALS, INC. (US) 2009-11-03 — — US disclosed
US-7612063-B2 Substituted quinobenzoxazine analogs CYLENE PHARMACEUTICALS, INC. (US) 2009-11-03 — — US disclosed
US-7507727-B2 Substituted quinobenzoxazine analogs and methods of using thereof CYLENE PHARMACEUTICALS, INC. (US) 2009-03-24 — — US disclosed
US-7507727-B2 Substituted quinobenzoxazine analogs and methods of using thereof CYLENE PHARMACEUTICALS, INC. (US) 2009-03-24 — — US disclosed
WO-2006078317-A1 SUBSTITUTED QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF CYLENE PHARMACEUTICALS, INC. (US) 2006-07-27 — — WO disclosed
CN-1809572-A Substituted quinobenzoxazine analogs CYLENE PHARMACEUTICALS INC (US) 2006-07-26 — — CN disclosed
US-20060029950-A1 Substituted quinobenzoxazine analogs and methods of using thereof CYLENE PHARMACEUTICALS, INC. 2006-02-09 — — US disclosed
EP-1610759-A2 SUBSTITUTED QUINOBENZOXAZINE ANALOGS Cylene Pharmaceuticals, Inc. (US) 2006-01-04 — — EP disclosed
US-20050085468-A1 Substituted quinobenzoxazine analogs CYLENE PHARMACEUTICALS 2005-04-21 — — US disclosed
WO-2004091504-A2 SUBSTITUTED QUINOBENZOXAZINE ANALOGS CYLENE PHARMACEUTICALS, INC. (US) 2004-10-28 — — WO disclosed
EP-0457090-B1 Process for the preparation of 3-amino-2 (het)aroyl-acrylic acid derivatives BAYER AG (DE) 1995-11-29 — — EP disclosed
US-5182401-A Bactericide intermediate BAYER AKTIENGESELLSCHAFT (DE) 1993-01-26 — — US disclosed
EP-0457090-A2 Process for the preparation of 3-amino-2 (het)aroyl-acrylic acid derivatives BAYER AG (DE) 1991-11-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085468-A1 Substituted quinobenzoxazine analogs CYP3A5, UGT2B7, CYP2D6 MEN1 3714/4885KMT2A 1689/4885NPSR1 370/4885
US-20120122804-A1 SUBSTITUTED QUINOBENZOXAZINE ANALOGS CYP3A5, UGT2B7, CYP2D6 MEN1 3714/4885KMT2A 1689/4885NPSR1 370/4885
US-20110065687-A1 HYDRAZIDE COMPOUNDS AND USES THEREOF EIF2AK2, DDX21, POLI MEN1 2881/4885KMT2A 1555/4885NPSR1 4451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.